Skip to main content

Table 2 Means and standard deviations of SNV predicted neoantigens, mutations/Mb of non-silent mutations and TIL fractions in the indicated tumor populations

From: RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer

 

SNVneoantigens (predicted)a

NonsilentMUTS (muts/Mb)b

TILs fraction (%)c

DWT

84.7 ± 86.3

5.0 ± 5.3

6.0 ± 6.4

RB1 only

141.6 ± 145.1

8.2 ± 7.8

7.8 ± 6.6

TP53 only

102.7 ± 81.4

6.4 ± 4.7

7.6 ± 6.3

RB1&TP53

135.6 ± 101.4

8.4 ± 6.2

9.1 ± 7.8

Kruskal-Wallis (p value)

a < 0.001

b < 0.001

c 0.002

RB1 WT

91.2 ± 84.8

5.5 ± 5.1

6.6 ± 6.4

RB1 MUT

117.1 ± 85.4

7.3 ± 5.2

8.6 ± 8.2

RB1 HD

180.3 ± 158.5

10.5 ± 8.8

8.7 ± 5.6

Kruskal-Wallis (p value)

a < 0.001

b < 0.001

c 0.015

TP53 WT

93.5 ± 99.3

5.5 ± 5.9

6.3 ± 6.4

TP53 TRUNCATED

106.6 ± 90.0

7.1 ± 5.9

9.1 ± 8.3

TP53 MISSENSE

123.7 ± 91.9

7.5 ± 5.1

7.8 ± 6.1

Kruskal-Wallis (p value)

a < 0.001

b < 0.001

c 0.002